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Renal artery resistive indexAbstract Background: Relationship between uric acid and renal artery resistive index (RRI) in
hypertensive subjects was recently suggested.
Aim: The aim was to evaluate the effect of hyper-uricemia on RRI in adult Egyptian subjects with
no other risk factors of renal vascular disease, and to assess the impact of therapeutic control of
serum uric acid on the RRI.
Patients and methods: 50 adult hyper-uricemic subjects were included in this study, who underwent
abdominal ultrasound with Doppler examination of the kidneys. The RI was automatically calcu-
lated by the US equipment. Intra-renal resistance was measured at inter-lobar arteries three times in
different regions of each kidney (upper, middle, and lower zones) and the mean RI value was cal-
culated. Each case had its pre and post 3 and 6 weeks treatment duplex measurement of RI together
with uric acid measurement and correlation.
Results: Mean value of the baseline RI was 0.768 ± 0.01355 SD, and mean serum uric acid value
was 10.86 ± 0.65 SD, with a positive signiﬁcant correlation between both values. Mean value of the
difference of the serum uric acid level and RRI prior to and 3 weeks after treatment was
2.68 ± 0.49, 0.04 ± 0.01 respectively, with positive signiﬁcant correlation between the two values
p-value: 0.001. Mean value of the difference of the serum uric acid level and RRI 3 and 6 weeks after
treatment was 2.18 ± 0.5 and 0.06 ± 0.01 respectively, with signiﬁcant positive correlation between
the two values and p-value 0.00. Mean value of the total change of serum uric acid and RRI over the
treatment period was: 2.38 ± 0.43 and 0.049 ± 0.01 with positive signiﬁcant correlation between
the two values and p-value: 0.00.
1206 A.M. Hussein et al.Conclusion: Serum uric acid signiﬁcantly correlates with RRI in the absence of other risk factors
affecting renal vasculature. Improvement of serum uric acid is accompanied by the improvement
in RRI.
 2015 The Authors. The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting
by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
The resistive index of an artery is a hemodynamic measure
considered to reﬂect its vascular impedance (1). Higher resis-
tive index values consist in a manifestation of local arteri-
olopathy (2). Evaluation of vascular impedance at different
sites of the renal parenchyma may suggest functional or struc-
tural changes within the kidneys and could provide useful
diagnostic and prognostic information (3).
Indeed, the Doppler-derived renal resistive index (RRI) has
been used in the assessment of chronic renal allograft rejection
(4), detection and management of renal artery stenosis (5),
evaluation of progression risk in chronic kidney disease
(CKD) (6), and more recently as a predictor of renal and over-
all outcome in the critically ill patient (7).
Experimental data showed that uric acid stimulates
proliferation, inﬂammation and oxidative stress in vascular
smooth-muscle cells, induces endothelial dysfunction and
activates the renin–angiotensin system (8).
Recent data demonstrated an independent relationship
between uric acid and renal artery resistive index in hyper-
tensive subjects, indicating that uric acid might be associated
with microvascular damage and/or dysfunction in clinical
settings (9).
However there were limitations in the literature in studying
the effect of hyper-uricemia on renal artery resistive index in
the absence of other risk factors of renal vascular disease e.g.
diabetes and hypertension.
1.1. Aim of the study
This study was designed to evaluate the effect of hyper-
uricemia on RRI in adult Egyptian subjects with no other risk
factors of renal vascular disease, and to assess the impact of
therapeutic control of serum uric acid on the RRI.
2. Patients and methods
2.1. Patients
Our study comprised a total of 50 nonsmoking, non-diabetic,
non-hypertensive, recently diagnosed hyperuricemic (serum
uric acid > 7.0 mg/dL standard laboratory tests) otherwise
healthy subjects attending the Internal Medicine outpatient
clinics of private hospitals for annual checkup as requested
by their companies.
All patients gave an informed consent before participating
in the study.
2.1.1. Exclusion criteria
Patients with hypertension (blood pressureP 140/90 mmHg),
diabetes mellitus (FBS > 126 mg/dl, 2hPP > 200 mg/dl),Hyperlipidemia, smoking, renal vascular or parenchymatous
diseases were excluded from the study.
All participants were subjected to the following:
1. Complete history taking and full physical examination
including blood pressure measurement test to exclude the
presence of hyper or hypo tension.
2. Laboratory testing including: serum uric acid, serum crea-
tinine to exclude renal decompensation patients, fasting
blood sugar and 2 h post prandial to exclude those with
Diabetes Mellitus and lipid proﬁle to exclude patients with
dyslipidemia.
3. All patients underwent Baseline pretreatment bi-
dimensional gray scale ultrasound and color duplex which
were used to exclude patients with:
 Arterial reno-vascular kidney disease (renal artery stenosis
manifested by decreased acceleration slope less than 3 meter
per squared second and/or prolonged acceleration time
more than 70 ms).
 Venous reno-vascular kidney disease (renal vein
thrombosis).
 Renal stones.
 Hydronephrosis.
 Renal size abnormalities (too small being below 95 mm in
length, too large being above 135 mm in length, or length
discrepancy between both sides more than 2 cm).
 Any grade of unilateral or bilateral abnormally increased
renal parenchymal echogenicity.
All these patients were excluded as all the previously
mentioned conditions affect the renal resistivity index.
Additionally patients with hemolytic anemias and hematolog-
ical malignancies were excluded from the study.
All patients received xanthine oxidase inhibitor
(Allopurinol 100–300 mg/day), and the renal resistivity index
was measured before treatment and after treatment phases of
3 and 6 weeks of the treatment.
2.2. Methods ﬁgures from 1 to 4
Each case had his pre and post 3 and 6 weeks treatment duplex
Doppler examination done by the same radiologist to avoid
inter-observer variabilities. Doppler angle was standardized
at 59.
Patients underwent abdominal ultrasound with duplex
Doppler examination of the kidneys. All subjects were exam-
ined after eight hours fasting. They underwent abdominal
ultrasonography (US) using US equipment with color
Doppler capability using convex linear (2.8–5 MHz) trans-
ducer (LOGIQ P6, General Electric Medical Systems, United
States of America). The RI was automatically calculated by
the US equipment. Intra-renal resistance was measured at
inter-lobar arteries three times in different regions of each
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was calculated. Subsequently, a mean RI was calculated
derived from 6 measurements for each patient.
3. Results
The study was conducted over 50 patients with hyper-
uricemia.
Patient demographics: all 50 patients were males with a
mean age of 37.5 years ± 4.61 years SD. The minimum, max-
imum and range of the age were 30, 45, and 15 respectively.
3.1. Analysis of patients’ data prior to medical treatment
Each participant underwent ultrasound Doppler examination
to calculate the renal arterial RI prior to the onset of medical
treatment. A total of 6 readings were obtained for both the
right and left renal arterial vasculature and a mean value was
calculated for all readings of both kidneys for each patient.
The mean value of the RI of the renal arterial vasculature
was 0.768 ± 0.01355 SD. The maximum, minimum and range
values of the RI were 0.79, 0.75, and 0.04 respectively (Figs. 1
and 4).
The serum uric acid value was obtained for each participant
prior to medical treatment. The mean serum uric acid value
was 10.86 ± 0.65 SD. The minimum, maximum and range val-
ues were 10, 12, 2 and respectively.
3.1.1. Correlation between the serum uric acid and renal artery
RI prior to treatment
No statistically signiﬁcant relation was found between the par-
ticipants’ ages and the level of serum uric acid nor betweenFig. 1 Showing renal artery ﬂow by spectral pulsed duplex with a
acid = 10.3).their age and the mean value of the renal arterial RI using
the one sample T-test, hence the null hypothesis could not be
rejected (p-values = 0.311, and 0.214 respectively).
As regards the relation between the serum uric acid and
renal arterial RI prior to the onset of therapy we were able
to reject the null hypothesis using chi-squared test where the
p-value = 0.001 (highly signiﬁcant).
In addition there was a positive correlation between both
values with a Pearson’s correlation coefﬁcient = 0.903 and
p-value 0.01 (Fig. 7 and Table 1).3.2. Analysis of patients’ data 3 weeks after onset of medical
treatment
The difference between the level of the serum uric acid 3 weeks
after and levels prior to medical treatment was calculated, with
estimation of the mean difference for each participant. The
same was done regarding the mean RI value for the same par-
ticipant prior to and 3 weeks after onset of treatment (Figs. 2
and 5).
Comparing the mean values of the calculated means of
the serum uric acid level differences prior to and after
onset of treatment to the same calculated renal arterial
RI values by using one sample T test, we were able to
reject the null hypothesis as regards a possible relation
between both variables, with a high signiﬁcance
(p-value = 0.001).
In addition correlation between both variables using
bivariate correlation method showed positive correlation
with a Pearson’s correlation coefﬁcient of 0.517, covari-
ance value of 0.003 and p-value 0.001 (Fig. 8 and
Table 2).utomated RRI calculation before initiation of treatment (S. uric
Fig. 2 Showing renal artery ﬂow by spectral pulsed duplex with automated RRI calculation 3 weeks after treatment (S. uric acid = 7.9).
Fig. 3 Showing renal artery ﬂow by spectral pulsed duplex with automated RRI calculation 6 weeks after treatment and achieving
normal serum uric acid level (S. uric acid = 6).
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treatment
The difference between the level of the serum uric acid 3 and
6 weeks after onset of medical treatment was calculated, withestimation of the mean difference for each participant. The
same was done regarding the mean RI value for the same 3
and 6 weeks after onset of treatment (Figs. 3 and 6).
Comparing the previously calculated serum uric acid and
renal arterial RI differences using one sample T test, we were
Table 1 Mean values of serum uric acid and RI of renal arterial vasculature in patients with hyper-uricemia prior to treatment.
Mean value ± SD Minimum Maximum Range p-value Pearson’s correlation coeﬃcient
Serum uric acid 10.86 ± 0.65184 10 12 2 0.01 0.903
Renal arterial RI 0.768 ± 0.01355 0.75 0.79 0.04
Fig. 4 Showing renal artery ﬂow by spectral pulsed duplex with automated RRI calculation before initiation of treatment in another
patient (S. uric acid = 11.5).
Fig. 5 Showing renal artery ﬂow by spectral pulsed duplex with automated RRI calculation 3 weeks after treatment in another patient
(S. uric acid = 9).
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Fig. 6 Showing renal artery ﬂow by spectral pulsed duplex with automated RRI calculation 6 weeks after treatment and achieving
normal serum uric acid level (S. uric acid = 6.7).
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Fig. 7 Scatter plot depicting the values of the serum uric acid
plotted against the mean value renal arterial RI in the participat-
ing patients prior to treatment.
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relation between both variables, with a high signiﬁcance
(p-value = 0.00).
In addition correlation between both variables using bivari-
ate correlation method showed positive correlation with a
Pearson’s correlation coefﬁcient of 0.544, covariance value of
0.004 and p-value: 0.00 (Fig. 9 and Table 3).
Finally, the mean value of the difference of the serum uric
acid levels measures prior to, 3, and 6 weeks after the onset of
medical treatment was calculated. The same was done for the
mean renal arterial RI for the same patients.
The values of the mean difference of the serum uric acid cal-
culated in the previous step were compared to those of thedifference in RI for the same participants using one sample
T-test, and the null hypothesis could be rejected with high
signiﬁcance of the p-value (0.00).
Correlation using bivariate correlation method was done
with conﬁrmed positive correlation of both variables with
Pearson’s correlation coefﬁcient = 0.903, covariance = 0.004
and p-value: 0.00 (Fig. 10 and Table 4).
4. Discussion
The renal resistive index (RRI) is commonly used as an index
of intra-renal arterial resistance (10). RI increases in various
kidney diseases (11), and previous studies have shown the asso-
ciations of RI with renal function and patient prognosis (12).
Uric acid is the end product of human purine metabolism.
Increased serum uric acid has been considered with different
metabolic, cardiovascular, and renal disorders (13). Hyper-
uricemia is closely associated with chronic kidney disease
(CKD), is a risk factor for renal insufﬁciency in general popu-
lations, and is a poor prognostic factor of renal function in
patients who have nephropathy (14). Glomerular, tubulointer-
stitial, and vascular involvement (15) with eventual chronic
renal disease has been reported in hyper-uricemia (16).
Recognition of the different manifestations and complications
of hyper-uricemia seems beneﬁcial to prevent renal damage in
the early phase (17). Effect of hyper-uricemia as a sole cause of
increased renal resistive index with no other risk factors- has
not been widely studied.
The current study shows signiﬁcant correlation between
baseline serum uric acid values and the RRI. This reﬂects the
effect of hyper-uricemia -in the absence of any other risk factor
of renal vascular affection such as hypertension, diabetes,
hyperlipidemia and senile atherosclerosis-on RRI. This shows
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Fig. 8 Scatter plot depicting the mean differences of the serum uric acid prior to and 3 weeks after onset of treatment plotted against the
RI differences for the same patients.
Table 2 Table representing the mean value of the difference of the serum uric acid level and renal arterial RI prior to and 3 weeks
after treatment.
Mean ± SD p-value Pearson’s correlation
coeﬃcient
Covariance
Mean value of the diﬀerence of the serum uric acid
level prior to and 3 weeks after treatment
2.68 ± 0.49857 0.001 0.517 0.003
Mean value of the diﬀerence of the renal artery
RI prior to and 3 weeks after treatment
0.0402 ± 0.01237
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Fig. 9 Scatter plot depicting the mean differences of the serum
uric acid 3 and 6 weeks after onset of treatment plotted against the
RI differences for the same patients.
Table 3 Table representing the mean value of the difference of the serum uric acid level and renal arterial RI 3 and 6 weeks after
treatment.
Mean ± SD p-value Pearson correlation Covariance
Mean value of the diﬀerence of the serum uric acid
level 3 and 6 weeks after treatment
2.182 ± 0.56737 0.00 0.544 0.004
Mean value of the diﬀerence of the renal artery RI 3
and 6 weeks after treatment
0.06 ± 0.01429
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Fig. 10 Scatter plot depicting the mean differences of the serum
uric acid prior to, 3 and 6 weeks after onset of treatment plotted
against the RI differences for the same patients.
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Table 4 Table representing the mean value of the difference of the serum uric acid level and renal arterial RI prior to, 3 and 6 weeks
after treatment.
Mean ± SD p-value Pearson
correlation
Covariance
Mean value of the total change of serum uric acid prior to,
3 and 6 weeks after treatment
2.384 ± 0.43 0.00 0.903 0.004
Mean value of the total change of renal artery RI prior to,
3 and 6 weeks after treatment
0.0493 ± 0.01
1212 A.M. Hussein et al.some similarity to the results of a study done by Berni et al.,
who found that hyperuricemics had signiﬁcantly higher RRI
than normouricemics but in hypertensive patients indicating
that serum uric acid might be associated with microvascular
damage and/or dysfunction in clinical settings (2). Hyper-
uricemia was found to result in the activation of renin–an-
giotensin system, down-regulation of nitric oxide, vascular
muscle proliferation, afferent arteriolosclerosis, altered pres-
sure natriuresis, endothelial dysfunction, and abnormal cellu-
lar sodium transport (18), all of these factors may explain
the increase in RRI and its correlation with hyper-uricemia
in the current study. These results are also similar to results
of Messerli et al., who found that renal blood ﬂow was lower
and renal vascular and total peripheral resistances were
increased in patients with high uric acid levels (19).
Different results were observed by Pontremoli et al., who
found that the degree of RI correlated with age, blood pres-
sure, target organ damage despite similar body mass index,
uric acid, fasting blood glucose, lipid proﬁle and duration of
hypertension upon their patients (20).
This study also revealed signiﬁcant correlation between
serum uric acid and RRI after 3 and 6 weeks of medical treat-
ment of hyper-uricemia using xanthine oxidase enzymes inhibi-
tor (Allopurinol) (21), denoting signiﬁcant positive impact of
the management of hyper-uricemia on renal resistive index.
Similar results were reached by Nickavar et al., who observed
that proteinuria decreased signiﬁcantly by uric acid lowering
agents and antiproteinuric treatment in a patient with familial
juvenile hyperuricemic nephropathy (17). Sezer et al., found
that allopurinol treatment decreased cardiovascular risk fac-
tors and slowed the progression of renal disease pre-dialysis
chronic kidney disease patients with hyper-uricemia (22).
Allopurinol, by decreasing the serum UA levels, may serve
as an agent to decrease glomerular hydrostatic pressure indi-
rectly and thus help alleviate the renal damage. Kanbay
et al. reported that the treatment of asymptomatic hyper-
uricemia improved renal function (23). Likewise, Siu et al.
reported that the treatment of asymptomatic hyper-uricemia
delayed disease progression (24).
5. Conclusion
There is signiﬁcant correlation between serum uric acid and
renal resistive index. Management of hyper-uricemia results
in lowering of serum uric acid which correlates signiﬁcantly
with the decrease in RRI.
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